Douglas Taylor Falk
Gründer bei Vita Therapeutics, Inc.
Aktive Positionen von Douglas Taylor Falk
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Vita Therapeutics, Inc.
Vita Therapeutics, Inc. BiotechnologyHealth Technology Vita Therapeutics, Inc. is a biotechnology company based in Baltimore, MD that develops state-of-the-art cellular therapeutics for the treatment of neuromuscular diseases and cancers. The company uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. Vita Therapeutics is progressing its co-leading programs VTA-100 and VTA-300 for the treatment of limb-girdle muscular dystrophy (LGMD) and multiple solid tumors with the goal of filing investigational drug applications with the Food and Drug Administration in 2023. The company is developing these proprietary cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line. Vita Therapeutics was founded in 2019 by Douglas Taylor Falk, M.S. and Peter Andersen, Ph.D. Douglas Taylor Falk has been the CEO since 2019. | Direktor/Vorstandsmitglied | 01.01.2019 | - |
Vorstandsvorsitzender | 01.01.2019 | - | |
Gründer | 01.01.2019 | - |
Karriereverlauf von Douglas Taylor Falk
Ehemalige bekannte Positionen von Douglas Taylor Falk
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Brown Advisory LLC
Brown Advisory LLC Investment ManagersFinance Brown Advisory LLC is a SEC-registered investment advisor headquartered in Baltimore, Maryland. The firm is a subsidiary of Brown Advisory Management LLC and their ultimate parent is Brown Advisory, Inc. The firm was founded and launched in 1993 as an investment management division of Alex. Brown & Sons, a Baltimore-based investment bank founded in 1800. In 1998, they became independently owned through an employee-led buyout. Brown Advisory provides investment management services to individuals and institutions. | Analyst-Equity | 01.01.2015 | 01.01.2019 |
Ausbildung von Douglas Taylor Falk
Goucher College | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Operativ
Analyst-Equity | 1 |
Undergraduate Degree | 1 |
Director/Board Member | 1 |
Sektoral
Finance | 2 |
Consumer Services | 2 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Brown Advisory LLC
Brown Advisory LLC Investment ManagersFinance Brown Advisory LLC is a SEC-registered investment advisor headquartered in Baltimore, Maryland. The firm is a subsidiary of Brown Advisory Management LLC and their ultimate parent is Brown Advisory, Inc. The firm was founded and launched in 1993 as an investment management division of Alex. Brown & Sons, a Baltimore-based investment bank founded in 1800. In 1998, they became independently owned through an employee-led buyout. Brown Advisory provides investment management services to individuals and institutions. | Finance |
Vita Therapeutics, Inc.
Vita Therapeutics, Inc. BiotechnologyHealth Technology Vita Therapeutics, Inc. is a biotechnology company based in Baltimore, MD that develops state-of-the-art cellular therapeutics for the treatment of neuromuscular diseases and cancers. The company uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. Vita Therapeutics is progressing its co-leading programs VTA-100 and VTA-300 for the treatment of limb-girdle muscular dystrophy (LGMD) and multiple solid tumors with the goal of filing investigational drug applications with the Food and Drug Administration in 2023. The company is developing these proprietary cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line. Vita Therapeutics was founded in 2019 by Douglas Taylor Falk, M.S. and Peter Andersen, Ph.D. Douglas Taylor Falk has been the CEO since 2019. | Health Technology |
- Börse
- Insiders
- Douglas Taylor Falk
- Erfahrung